ClinicalTrials.gg
RecruitingNCT07702266PHENOPAINUpdated Nov 17, 2026

Primary Parkinsonian Pain: Clinical Association and Phenotype

An observational study in Parkinson s Disease, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 17, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · University Hospital, Clermont-Ferrand.

Started
2026
with 2 others
Observational
2 of 25
1 open now
Registered
23rd of 25
by date

Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, this one is one of 3 that started in 2026, is one of 2 observational ones, and was the 23rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

Among the different types of pain observed in Parkinson's disease, primary parkinsonian pain (PPP) is the most severe, the most difficult to treat, but also the least well characterized and the hardest to describe, not only by patients but also by neurologists. Consequently, PPP remains difficult to identify, even for clinicians with expertise in Parkinson's disease.

Nevertheless, patients with Parkinson's disease who experience PPP appear to exhibit certain demographic and clinical characteristics that may help distinguish them from other patients, including a poorer motor response to levodopa, a stronger association with sleep disturbances, and cognitive and behavioral features such as impulse control disorders (ICDs). PPP may therefore be associated with a specific disease phenotype supported by distinct pathophysiological mechanisms.

Recently, a disease progression model proposed the existence of a "Brain-First" subtype (characterized by disease onset in the brainstem) and a "Body-First" subtype (characterized by disease onset in the gastrointestinal system). Several clinical markers appear to distinguish these subtypes, notably the presence of REM sleep behavior disorder (RBD), which has been associated with the Body-First phenotype.

The association between PPP and RBD, as well as between PPP and the Body-First subtype, has never been investigated. We hypothesize that PPP may be associated with several clinical markers of the Body-First phenotype. Identifying such associations could facilitate the routine clinical diagnosis of PPP and, consequently, improve its management, which remains inadequate at present.

The primary objective is to assess the proportion of patients with primary parkinsonian pain according to the presence of probable RBD in Parkinson's disease.

This prospective, cross-sectional, non-interventional category 3 study (RIPH 3) will be conducted in 300 patients. Patients contacted through the France Parkinson Association and interested in participating in the study will be able to access the online questionnaire via a QR code or a web link. Completion of the questionnaire is expected to take no more than 15 minutes. This self-administered questionnaire will include collection of general data (age, sex, disease duration, initial motor symptoms, side of symptom onset predominance, and comorbidities), assessments of pain, migraine, sleep, constipation, olfaction, anxiety and depression and impulse control disorders.

03

Conditions studied

  • Parkinson s Disease

Keywords

  • Parkinson's disease
  • RBD
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be contacted through the France Parkinson Association. If interested in the study, they will be able to access the online questionnaire hosted on the REDCap platform via a QR code or a web link.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • French-speaking.
  • Diagnosis of Parkinson's disease confirmed by a neurologist.

Exclusion criteria

Exclusion Criteria:

  • Atypical parkinsonian syndrome.
  • Patients under legal protection (guardianship, curatorship, or legal safeguard measures).
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Parkinsonian patients

    Patients with a diagnosis of Parkinson's disease confirmed by a neurologist

    Other: Online self-administered questionnaire

Interventions

  • OtherOnline self-administered questionnaire

    Completion of the questionnaire is expected to take no more than 15 minutes. This self-administered questionnaire will include collection of general data (age, sex, disease duration, initial motor symptoms, side of symptom onset predominance, and comorbidities), assessments of pain, migraine, sleep, constipation, olfaction, anxiety and depression and impulse control disorders.

06

What researchers measure

Primary outcomes

  1. Presence of primary parkinsonian pain according to the 3PDQ questionnaire

    This self-questionnaire is completed by the patient during the inclusion visit

    Time frame: at day 0

  2. Probable REM sleep behavior disorder (RBD), as identified using the RBD-1Q (REM Sleep Behavior Disorder Single-Question Screen).

    This self-questionnaire is completed by the patient during the inclusion visit

    Time frame: at day 0

Secondary outcomes

  1. Presence of anosmia

    Self-reported olfactory dysfunction

    Time frame: at day 0

  2. Presence of constipation

    Self-reported constipation dysfunction

    Time frame: at day 0

  3. Presence of impulsive control disorders

    Self reported impulse control disorders

    Time frame: at day 0

  4. Presence of Anxiety and/or depression according the HADs (Hospital Anxiety and Depression scale)

    This self-questionnaire is completed by the patient during the inclusion visit

    Time frame: at day 0

  5. Presence of RBD according the RBD SQ (RBD-Screening Questionnaire)

    This self-questionnaire is completed by the patient during the inclusion visit

    Time frame: at day 0

  6. Pain intensity according an EVA scale

    patients will evaluate their pain with an EVA scale at inclusion visit

    Time frame: at day 0

  7. Presence of comorbidities

    Patients will report if they had comorbidities such as diabete or osteoarticular disorders.

    Time frame: at day 0

  8. presence of migraines

    patient will report if he had migraines

    Time frame: at day 0

  9. Current antiparkinsonian and analgesic treatments

    Patient will report his current antiparkinsonian and analgesic treatments

    Time frame: at day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 10 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 14, 2026
StartActual
Nov 3, 2026was Sep 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Oct 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
CHU Clermont-Ferrand is now Recruiting
Nov 17, 2026
Start date
Sep 2026→Nov 3, 2026 (actual)
Nov 17, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPrsencePresence of RBD according the RBD SQ (RBD-Screening Questionnaire)Time frame: at day 0
  • ChangedBefore Presence of impulsive control disorders according the QUIP-Anytime During PD-Short (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease)Now Presence of impulsive control disordersTime frame: at day 0
Oct 16, 2026
Show all 2 updates
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    CHU Clermont-Ferrand is now Recruiting
    Start date Sep 2026→Nov 3, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 16, 2026
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPrsencePresence of RBD according the RBD SQ (RBD-Screening Questionnaire)Time frame: at day 0
    • ChangedBefore Presence of impulsive control disorders according the QUIP-Anytime During PD-Short (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease)Now Presence of impulsive control disordersTime frame: at day 0

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07702266
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Nov 3, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
+33473754963

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion